Call Us for Support
+91 9654860915
Finding access to medicine unapproved in your home country can feel overwhelming. We’re here to help you navigate the process, from your initial request to procurement coordination.
Submit your details and prescription to get started.Register today to get started on your medicine access journey.
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
Ready to proceed? Order Margenza on our secure patient portal to submit your prescription, upload documents and track your approval status.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
TerSera Therapeutics LLC
Regulatory Approval:
Your Trustworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Margenza (margetuximab) is an antibody infusion for HER2-positive metastatic breast cancer. In the United States it is approved, together with chemotherapy, for adults whose cancer has spread and who have already received two or more HER2-targeted treatments, at least one of them for metastatic disease.
It is meant for later lines of treatment, when earlier HER2 medicines have stopped working. It is given in hospital by an oncologist. Read more about imported medicines for breast cancer and our oncology medicines.
Margenza attaches to HER2, a protein found in large amounts on some breast cancer cells. This slows the growth of the cancer cells. Its tail end (the Fc region) has been engineered to bind more strongly to the receptors on immune cells that kill tumour cells, and less to the receptors that hold them back. In lab studies this led to a stronger immune attack on the cancer (ADCC).
The SOPHIA study included 536 patients with HER2-positive metastatic breast cancer who had already received several HER2 treatments. Patients received Margenza or the standard HER2 antibody, each with the doctor's choice of chemotherapy (capecitabine, eribulin, gemcitabine or vinorelbine).
Your oncologist will explain whether this benefit suits your situation.
The dose is 15 mg per kg of body weight as an intravenous infusion every 3 weeks, until the disease progresses or side effects become too much. The first infusion runs over 120 minutes; later infusions take at least 30 minutes. On days when chemotherapy is also given, Margenza can be infused straight after the chemotherapy. If a dose is missed, it is given as soon as possible and the 3-week gap is kept from then on.
This information is not a treatment plan. For personalized medical advice, consult your doctor and refer to the full prescribing information.
Margenza can weaken the heart's pumping power (left ventricular ejection fraction, LVEF). In SOPHIA this happened in 1.9% of patients. An echocardiogram or MUGA scan is needed within 4 weeks before starting and every 3 months during treatment. Treatment is paused if LVEF drops by a set amount, and stopped for good if it does not recover within 8 weeks. It has not been studied in people with LVEF below 50%, a recent heart attack or heart failure. Report breathlessness, swollen ankles, a racing heart or sudden weight gain.
HER2 antibodies used during pregnancy have caused too little amniotic fluid, poor lung and bone development and death of the newborn. A pregnancy test is done before starting. Women who can become pregnant should use effective contraception during treatment and for 4 months after the last dose.
Infusion reactions occurred in 13% of patients, mostly in the first cycle, and were severe in 1.5%. Signs include fever, chills, cough, dizziness, rash, a fast heartbeat and low blood pressure. All resolved within 24 hours. The nurse slows or stops the infusion if a reaction happens.
With chemotherapy, the most common side effects were tiredness, nausea, diarrhoea, vomiting, constipation, headache, fever, hair loss, stomach pain, numbness or tingling (neuropathy), joint and muscle pain, cough, loss of appetite, breathlessness and redness or peeling on the palms and soles. Many of these come from the chemotherapy given with it. This is not a complete list.
This information is not a treatment plan. For personalized medical advice, consult your doctor and refer to the full prescribing information.
Margenza is not sold in Indian pharmacies, so every order is arranged for one named patient. As it is given every 3 weeks, we plan the supply cycle by cycle.
Send the prescription with the chemotherapy it will be given with, the patient's current weight and the planned number of cycles. The dose is 15 mg/kg, so a 60 kg patient needs 900 mg per infusion, which means four 250 mg vials. Our pharmacist confirms the vial count for each cycle.
A registered pharmacist checks the prescription, the HER2-positive report, the list of earlier HER2 treatments and the patient's ID, and tells you at once if anything is missing.
The Margenza price in India is quoted for the vials needed per 3-week cycle, plus cold-chain freight and customs clearance.
We prepare the Form 12A application to CDSCO under Rule 36 of the Drugs and Cosmetics Rules. CDSCO states the Form 12B permit is usually issued within one to two days and stays valid for six months.
The vials travel at 2°C to 8°C in their original cartons, with a temperature logger in every box.
We deliver to the hospital pharmacy or day-care unit, timed to the chemotherapy day.
The permit step usually takes one to two working days once all documents are complete. We share the expected delivery date with the quote, as it depends on stock at source and the flight route.
No. Margenza (margetuximab) has no marketing approval in India and is not sold in Indian pharmacies. We checked the published minutes of CDSCO's oncology and haematology expert committees from 2018 to November 2026, and margetuximab does not appear in them. It is also not authorised in the European Union, so supply comes from the United States. It can still be imported legally for a named patient under Rule 36, with a Form 12A application and a Form 12B permit.
Margenza comes as a 250 mg/10 mL single-dose vial, in cartons of one or four. The number of vials per cycle depends on body weight. People often search for the margetuximab 250 mg price, but the cycle cost depends on weight and the number of cycles.
Not from an open online store, because a medicine without Indian approval cannot be sold off the shelf. The legal way is to send the prescription to NPP online, and we arrange the permit and import in the patient's name.
Patients from Nepal, Bangladesh, Bhutan, Sri Lanka and the Gulf can also ask us, subject to each country's import rules. Read our guide to Indian import regulations for the full legal process.
Margenza is made by TerSera Therapeutics in the United States. As a Margenza supplier in India under the named patient route, NPP buys it only through authorised channels and only after the patient's permit is issued, so every vial can be traced to one patient and one prescription.
Unopened vials must be kept in a refrigerator at 2°C to 8°C, in the original carton to protect them from light. They must not be frozen or shaken. We ship in validated insulated boxes with a data logger and check the temperature record on arrival. Read more about our temperature-controlled shipping.
The hospital pharmacy dilutes the vials in a saline bag just before use. Per the US label, the prepared bag can be kept for up to 4 hours at room temperature or up to 24 hours in the fridge. This is why we time each delivery close to the infusion day.
A registered pharmacist matches every order with the prescription and the permit before it leaves New Delhi.
For the Margenza cost in India and current availability, contact NPP via WhatsApp at +91 98104 69557 | Toll-Free: 1800-1200-365 or email info@namedpatientprogram.com.
Margenza is given in hospital oncology day-care units, so we deliver to the hospital where the patient has chemotherapy, timed to each 3-week cycle.
See how we arrange delivery of imported medicines to hospitals across India.
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message